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Survival motor neuron protein reduction deregulates
autophagy in spinal cord motoneurons in vitro
A Garcera1, N Bahi1, A Periyakaruppiah1, S Arumugam1 and RM Soler*,1
Spinal muscular atrophy (SMA) is a genetic disorder characterized by degeneration of spinal cord motoneurons (MNs), resulting
in muscular atrophy and weakness. SMA is caused bymutations in the Survival Motor Neuron 1 (SMN1) gene and decreased SMN
protein. SMN is ubiquitously expressed and has a general role in the assembly of small nuclear ribonucleoproteins and
pre-mRNA splicing requirements. SMN reduction causes neurite degeneration and cell death without classical apoptotic
features, but the direct events leading to SMN degeneration in SMA are still unknown. Autophagy is a conserved lysosomal
protein degradation pathway whose precise roles in neurodegenerative diseases remain largely unknown. In particular, it is
unclear whether autophagosome accumulation is protective or destructive, but the accumulation of autophagosomes in the
neuritic beadings observed in several neurite degeneration models suggests a close relationship between the autophagic
process and neurite collapse. In the present work, we describe an increase in the levels of the autophagy markers including
autophagosomes, Beclin1 and light chain (LC)3-II proteins in cultured mouse spinal cord MNs from two SMA cellular models,
suggesting an upregulation of the autophagy process in Smn (murine survival motor neuron protein)-reduced MNs.
Overexpression of Bcl-xL counteracts LC3-II increase, contributing to the hypothesis that the protective role of Bcl-xL observed
in some SMAmodels may be mediated by its role in autophagy inhibition. Our in vitro experimental data indicate an upregulation
in the autophagy process and autophagosome accumulation in the pathogenesis of SMA, thus providing a valuable clue in
understanding the mechanisms of axonal degeneration and a possible therapeutic target in the treatment of SMA.
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Spinal muscular atrophy (SMA) is a genetic neuromuscular
disorder characterized by the degeneration of motoneurons
(MNs) in the anterior horn of the spinal cord, resulting in
muscular atrophy and weakness. SMA is caused by homo-
zygous disruption of the Survival Motor Neuron 1 (SMN1)
gene by deletion, conversion or mutation. In humans, the
SMN gene is present in multiple copies, oneSMN1 (telomeric)
and several SMN2 (centromeric) on chromosome 5q13.
SMN1 expresses a full-length transcript and SMN2 expresses
primarily a truncated isoform that is unable to compensate
SMN1 deficiency in SMA.SMN2 gene encodes for 10% of full-
length SMN, but results in inadequate levels of SMN. It is well
known that SMN protein level is critical to disease onset and
severity, and is determined in part by the SMN2 copy
numbers.1–3
One of the best characterized SMN functions is the
assembly of small nuclear ribonucleoprotein and pre-mRNA
splicing requirements, but the protein probably also has a
particular role in MN axons that results in appropriate levels of
certain transcripts in the distal axon and may contribute to
SMA pathogenesis.4–8 The direct events leading to MN
degeneration in SMA are still unknown. Although apoptotic
cell death has been proposed,9,10 no direct evidences of MN
apoptosis have been reported that demonstrate the
involvement of this process in SMA etiology. In some
neurodegenerative diseases, the cell death features inducing
neuronal loss do not fulfill the criteria of apoptosis,11
contributing to the hypothesis that other cell death processes
may bemediating neuronal degeneration in these disorders.12
Autophagy is a highly regulated, self-destructive process
that is important for differentiation, homeostasis and survival
under physiological and pathological conditions.13 Cytosolic
proteins and organelles are sequestered by a double
membrane and the resulting vacuoles (autophagosomes)
are delivered to lysosomes for degradation. Autophagy can
either be generally involved in the turnover of long-lived
protein and organelles, or specifically target distinct orga-
nelles (for example, mitochondria). Excessive autophagic
activity can lead to self-destruction and cell death, but
insufficient activity (or imbalanced autophagic flux) may also
contribute to cell death.
Alteration of the autophagy pathway is associated with
many neurodegenerative diseases and spinal cord injury.14–19
Although it is generally believed that autophagy is beneficial to
neuronal survival, its specific role in neurodegeneration
remains unclear. In particular, it is unclear whether autopha-
gosome accumulation is protective or destructive. For
instance, accumulation of autophagosomes in the neuritic
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beadings observed in several neurite degeneration models
suggests a close relationship between the autophagic
process and neurite collapse.20,21
The present study explored autophagy in a cellular model of
SMA. Our previous work demonstrated that murine survival
motor neuron protein (Smn) knockdown causes neurite
degeneration and late cell death in MNs. This phenotype
was rescued by the overexpression of the anti-apoptotic
protein Bcl-xL.
22 Here, we demonstrate increased autophago-
somes and the autophagy-related proteins Beclin1 and light
chain (LC)3-II in Smn-reduced MNs. The autophagosomes
are localized in MNs soma and neurites. Together, these
results suggest a deregulation of the autophagy process in
these cells. Moreover, the LC3-II protein increase is pre-
vented by Bcl-xL overexpression, suggesting that the protec-
tive role of this protein observed in some SMA models can be
mediated through its involvement in autophagy inhibition. Our
present data suggest an increase of autophagosome accu-
mulation in the pathogenesis of SMA, thus providing a
valuable clue in understanding the mechanisms of axonal
degeneration and a possible therapeutic target in the
treatment of SMA.
Results
Smn knockdown causes LC3-II protein increase. We
developed an in vitro model of SMA using a lentiviral RNA
interference method to downregulate the Smn protein level of
isolated mouse spinal cord MNs,22 and have now used this
model to analyze changes in the autophagy process in Smn-
reduced MNs (Figures 1a and b). An overall indicator of
autophagy impairment is the microtubule-associated pro-
teinLC3-II. Conversion of LC3-I into LC3-II has been
considered a general marker of autophagy initiation, and
LC3-II level is correlated with autophagosome quantity.23 To
analyze whether Smn reduction affects LC3-II protein levels,
MNs were transduced with a lentivirus containing empty
vector (EV) or short hairpin RNA sequences targeting
Phase contrast GFP
EV
GFP Smn
sh
Sm
n
EV Smn
Tubulin
Day 4 Day 6 Day 8 Day 12
EV
0.8
1
1.2
sh
Sm
n
0
0.2
0.4
0.6
Sm
n
pr
ot
ei
nl
ev
el
EV
shSmn
sh
Sm
n
EV sh
Sm
n
EV sh
Sm
n
EV sh
Sm
n
Day 12Day 8Day 6Day 4
Day 8Day 6 Day 12
EV
LC3-II
Tubulin
Smn
EV
LC3-II
Smn
Tubulin
LC3-II
Smn
Tubulin
EV     shSmn
LC3-I LC3-I LC3-I
0.6
0.8
1
1.2
1.4
1.6
1.8
2
LC
3-
II 
vs
 T
ub
ul
in *
0.6
0.8
1
1.2
1.4
1.6
1.8
2
LC
3-
II 
vs
 T
ub
ul
in
**
0.6
0.8
1
1.2
1.4
1.6
1.8
2
LC
3-
II 
vs
 T
ub
ul
in
*
0
0.2
0.4
EV shSmn
0
0.2
0.4
EV shSmn
0
0.2
0.4
EV shSmn
shSmn shSmn EVФ
LC3-II
Tubulin
Smn
LC3-I
1.5
1
0.5
0
non-trans
LC
3-
II 
vs
 T
ub
ul
in
EV
Figure 1 Effect of Smn reduction in LC3-II protein level. MNs were transduced with shSmn or EV lentiviral constructs or were left non-transduced (^) and maintained in
the presence of the NTFs cocktail (10 ng/ml of ciliary neurotrophic factor, glial cell line-derived neurotrophic factor, cardiotrophin-1, hepatocyte growth factor and 1 ng/ml of
brain-derived neurotrophic factor). (a) Representative microscopy images of 8 day-EV and shSmn-transduced cells maintained in the presence of NTFs: phase contrast (left)
and GFP (right), indicates GFP-expressing cells in the same microscopic field. Scale bar, 30 mm. (b) Representative confocal images of 8-day EV or shSmn cultures. Cells
were fixed and immunofluorescence with an anti-Smn antibody (blue) was performed. Scale bar, 15 mm. Protein extracts of 4-, 6-, 8- and 12-day-transduced cultures were
probed with an anti-Smn antibody by western blot and reprobed with an anti-a-tubulin antibody, used as a loading control. Graph represents the expression of Smn and
corresponds to the quantification of three independent experiments±S.E.M. (c and d) Protein extracts from 6-, 8- and 12-day EV or shSmn-transduced cultures (c); and 8
days EV or non-transduced (d) cultures were probed with an anti-LC3 antibody. Membranes were reprobed with an antibody against a-tubulin, used as a loading control, or an
anti-Smn antibody as protein reduction control. Graphs in c and d represent the expression of LC3-II versus a-tubulin and correspond to the quantification of at least four
independent experiments±S.E.M. Asterisks indicate significant differences using one-way ANOVA test and Bonferroni post-hoc multiple comparisons (*Po0.05;
**Po0.005)
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specific sites of mouse Smn (shSmn),22 and maintained in
the presence of the neurotrophic factors (NTFs) cocktail
(1 ng/ml brain-derived neurotrophic factor; 10 ng/ml glial cell
line-derived neurotrophic factor, 10 ng/ml ciliary neurotrophic
factor, 10 ng/ml cardiotrophin-1 and 10 ng/ml hepatocyte
growth factor). At 6, 8 and 12 days after transduction, cell
lysates were collected and submitted to western blot using an
anti-LC3 antibody. During SDS-polyacrylamide gel electro-
phoresis, LC3-II migrates faster than LC3-I, and the two
forms can be distinguished even though both are recognized
by anti-LC3 antibodies. Although LC3-II levels can be
calculated as a function of LC3-I, it has been suggested that
this relative analysis is not ideal for several reasons,
including delipidation of LC3-II, and differences between
tissues and cell lines in LC3-I levels.24 Thus, LC3-II levels as
a function of actin or tubulin (loading control) are thought to
be more reliable immunoblot measurements. Using this
approach, we observed a significantly increased LC3-II level
in shSmn cells after 6, 8 and 12 days of transduction,
compared with the EV control (Figure 1c). We also analyzed
LC3-II protein level in protein extracts at 4 days post-
transduction, but observed no differences between controls
and shSmn cells (data not shown). Protein extracts from non-
transduced cultures were also submitted to western blot in
order to discard changes in LC3-II level after lentiviral
transduction; no differences were observed (Figure 1c).
The increased LC3-II level in Smn-reduced MNs indicates
increased autophagosome generation and/or accumulation.
To localize the LC3-positive structures in cell somas and/or
neurites, we analyzed the endogenous LC3 protein by
immunofluorescence. MNs were plated on glass coverslips
and transduced using the EV or shSmn constructs. Eight
days after transduction, cells were fixed and LC3 immunos-
taining was performed. Figure 2 shows the distribution of
endogenous LC3-positive spots in both MN soma (Figure 2a)
and neurites (Figure 2b).
An increase in autophagosomes can result from increased
synthesis or from reduced degradation, which reflects an
alteration of the autophagic flux. To determine whether
increased autophagic synthesis or reduced autophagic flux
caused the LC3-II increase in Smn-reduced MNs, cultures
were treated with the lysosomal proteolysis inhibitor Baphilo-
mycin A1 (BafA1).25 This treatment causes LC3-II increase
when the autophagic flux is not altered.24 MNs were
transduced and, 8 days after plating, were treated or not with
BafA1 (50 nM during 4 h). Protein extracts were collected and
submitted to western blot analysis using the anti-LC3 anti-
body. When the lysosomal proteolysis is inhibited there is
an accumulation of autophagosomes in both conditions
(i.e., LC3-II is increased in shSmn condition, compared with
EV, but addition of BafA1 increases LC3-II in both conditions,
as shown in Figure 3). Of the possible outcomes of
autophagy modulation by a drug,24 this one indicates that
Smn reduction increases autophagosome synthesis without
affecting turnover.
Smn reduction increases autophagic structures in MNs.
Autophagosomes are double-membraned vesicles that med-
iate the first step of autophagy by sequestering organelles,
long-lived proteins, and/or portions of the cytoplasm. This
material is finally degraded by fusion with the lysosomal
compartment, forming the autolysosome.26,27 Transmission
electron microscopy is an important tool for detecting
autophagosomes and can provide significant insight to the
extent of on-going autophagy. We used this approach to
analyze the presence of autophagosomes and autolyso-
somes in the cytoplasm and neurites of Smn-reduced MNs.
The MNs were transduced with lentivirus containing EV or
shSmn, and after 8 days, MNs were processed and
analyzed. Non-transduced neurons were analyzed as a
control of the lentiviral transduction process (data not
shown). Smn reduction produced a marked increase in the
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Figure 2 Cellular distribution of LC3-II-positive aggregates. Representative
images of 8 days shSmn- or EV-transduced cultures. Cells were fixed and
processed for immunofluorescence with an anti-LC3 antibody. (a) Images of cell
soma and their emerging neurites. (b) Images of distant neurites. Arrows in a and b
indicate the presence of LC3-positive aggregates, in a and b, Hoechst (blue), GFP
(green). Scale bar: (a) 6mm and (b) 12mm. Images were acquired with an FV10I
confocal microscope (Olympus), using the  60 objective, and the same
microscopy settings. Images were not submitted to any post-capture manipulation
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number of autophagic profiles, including double-membraned
autophagosomes and autolysosomes (Figure 4). These
structures can be easily identified in MN soma and, on
average from three independent experiments, 0.46±0.18 of
autophagic compartments per MN soma were found in non-
transduced controls (n¼ 14) and EV (n¼ 14), whereas
2.66±0.45 of these structures per MN soma were found in
shSmn cultures (n¼ 16; Po0.0005). These autophagic
profiles were also found in neurites (Figures 4g and h).
Normal endoplasmic reticulum, Golgi complex and mitochon-
dria were found in EV- and shSmn-transduced neurons.
These results suggest an increase of the number of
autophagy profiles in Smn-reduced spinal cord MNs when
compared with non-transduced and EV controls.
Bcl-xL overexpression reduces LC3-II protein level in
Smn-reduced MNs. Smn protein knockdown causes neur-
ite degeneration and non-apoptotic cell death of spinal cord
MNs. This neurodegeneration can be prevented by Bcl-xL
overexpression without affecting Smn protein level.22 It is
known that Bcl-xL protein is an important factor in autophagy
through its binding to Beclin1 and inhibiting Beclin1-mediated
autophagy.28 To assess whether Bcl-xL overexpression
reduces autophagy in our model, the level of LC3-II protein
was analyzed in shSmn and EV cultures cotransduced
with lentivirus carrying an expression construct containing
the human Bcl-xL (hBcl-xL) gene. Eight days after
cotransduction, western blot analysis of protein extracts
showed that Bcl-xL was overexpressed. Overexpression
did not change Smn protein level compared with
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Figure 3 Effect of BafA1 on LC3-II protein level. MNs were transduced with EV
or shSmn, and 8 days later cells were treated with 50 nM BafA1 for 4 h. Cell extracts
were collected and submitted to western blot using an antibody against LC3. The
same membrane was reprobed with an anti-a-tubulin antibody as a loading control.
Graph represents the expression of LC3-II versus a-tubulin and correspond to the
quantification of three independent experiments±S.E.M. Asterisks indicate
significant differences using one-way ANOVA test and Bonferroni post-hoc multiple
comparisons (*Po0.05)
EV
shSmn
Figure 4 Ultrastructural changes in Smn-reduced spinal cord MNs. Mouse MNs
were transduced with lentivirus containing the EV (a and b) or shSmn (c–h)
construct. Cells were maintained in the presence of NTFs. Eight days after
transduction, cultures were fixed and submitted to electron microscopy. Arrows
indicate autophagic profiles present in cell somas (b–f) and neurites (g and h).
Scale bar: (a) 5 mm and (b–h) 1mm
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controls (Figure 5a). Compared with the EV control, LC3-II
level was 1.76±0.16 in shSmn, and 1.24±0.14 in hBcl-xL
and shSmn cotransduced cultures, indicating that Bcl-xL
significantly reduced the LC3-II protein levels (Po0.05). On
the other hand, Bcl-xL overexpression did not reduce LC3-II
protein in EV cells (1.05±0.11-fold increase compared with
EV controls), indicating that Bcl-xL reduces the LC3-II
increase caused by Smn knockdown.
Because Bcl-xL inhibits Beclin1-induced autophagy, we
wanted to know whether Beclin1 protein levels were affected
by Smn reduction. Total protein extracts of 8-day-transduced
MNs were analyzed using an anti-Beclin1 antibody. Beclin1
protein was slightly but significantly increased in shSmn
condition compared with the EV control (1.22±0.07-fold
increase, Po0.05). To assess whether Bcl-xL overexpression
prevented Beclin1 increase in Smn-reduced MNs, we
cotransduced these cells with both lentiviral constructs.
Western blot results indicated that Bcl-xL overexpression did
not reduce Beclin1 protein expression in EV or shSmn
conditions when compared with the non-Bcl-xL-transduced
controls (1.14±0.02- and 1.18±0.2-fold increase, respec-
tively) (data not shown). Taken together, these results show
an increase of Beclin1 protein after Smn reduction, and that
Bcl-xL overexpression prevents LC3-II, but not Beclin1,
increase.
LC3-II increases in MNs from a mouse model of SMA. To
determine whether changes in the level of LC3-II can also be
detected in MNs from an in vivo model of SMA, we used the
Smn( / ); SMN2 (SMA type I mice mutant, mtSMA) mouse
model for human type I SMA. Protein extracts were obtained
from cultures of isolated spinal cord MNs of mutant (mtSMA)
and wild-type (WT) animals. We dissected and genotyped
E13 embryos by crossing two Smn(þ / );SMN2 mutants.
After genotyping, MNs from WT and mtSMA embryos were
purified and cultured (Figure 6). Eight days after plating,
protein extracts were obtained and submitted to western blot
using anti-LC3 and anti-Beclin1 antibodies. As shown in
Figure 6, LC3-II protein was significantly increased in MNs
from mtSMA (1.65±0.12-fold increase, Po0.05) cultures
compared with the WT control. As we had observed in
shSmn conditions, Beclin1 levels were slightly increased in
mtSMA (1.23±0.1-fold increase; data not shown). Together,
these results suggest that cultured MNs obtained from an
in vivo model SMA show increased levels of autophagy
markers LC3-II and Beclin1, compared with MNs cultured
from their WT littermate embryos. This increase of LC3-II and
Beclin1 is comparable to that observed in shSmn-transduced
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Figure 5 Effect of Bcl-xL overexpression on LC3-II protein level. MNs were
cotransduced with lentivirus containing the hBcl-xL plus shSmn or the EV; or
transduced with EV or shSmn. (a) Protein extracts of 8 day-transduced cultures
were probed with an anti-LC3 or an anti-Bcl-xL antibody. (b) Protein extracts of 8
days were probed with an anti-Beclin1 antibody or an anti-Smn antibody.
Membranes were reprobed with an antibody against a-tubulin, used as a loading
control. Graph values in a and b represent the expression of LC3-II or Beclin1,
respectively, versus a-tubulin, and corresponds to the quantification of at least four
independent experiments±S.E.M. Asterisks indicate significant differences using
one-way ANOVA test and Bonferroni post-hoc multiple comparisons (*Po0.05)
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Figure 6 LC3 protein levels in MNs from SMA mice model. (a) Representative
images of 8 days cultures of isolated MNs from WT and Smn( / ); SMN2 (mtSMA)
embryos. Cells were cultured in the presence of the NTFs cocktail. Arrows indicate
neurite degeneration. Scale bar, 30 mm. (b) Protein extracts of EV and mtSMA of 8
days cultures were probed with an anti-LC3 antibody by western blot analysis.
Membranes were reprobed with an antibody against a-tubulin as a loading control.
Graph values represent the expression of LC3-II versus a-tubulin and corresponds
to the quantification of three independent experiments±S.E.M. Asterisks indicate
significant differences using one-way ANOVA test and Bonferroni post-hoc multiple
comparisons (*Po0.05)
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MNs, reinforcing the hypothesis that Smn-reduced MNs
undergo changes related to autophagy.
Discussion
In the present study, we described an increase in the levels of
the autophagy markers in MNs obtained from SMA models.
Smn protein reduction caused an increment of the autopha-
gosome number as well as of the autophagy-related proteins
Beclin1 and LC3-II. Our group’s main research agenda is to
analyze the cellular and molecular events involved in MN
degeneration caused by Smn protein reduction. We pre-
viously described that Smn knockdown causes neurite
degeneration and late non-apoptotic cell death, both of which
are prevented by Bcl-xL overexpression.
22 It is known that Bcl-
xL inhibits autophagy by binding to Beclin1, which is required
for the initiation of autophagosome formation.28,29
In order to study the molecular process that leads Bcl-xL
protein to counteract the Smn knockdown degenerative
process, we decided to analyze the autophagy in Smn-
reduced MNs. We observed an increase of the autophago-
some formation that can be prevented by Bcl-xL. Thus, we
propose two promising avenues for further research: autop-
hagy deregulation as a contributor to MN degeneration in
SMA disease and the protective effect of the Bcl-xL pathway in
Smn-reduced MNs.
Among the list of molecular and cellular approaches to
assess autophagy deregulation, two are considered key
methods: autophagosome detection by electron micro-
scopy24,27 and the presence of LC3-II.23,30,31 In our model,
electron microscopy showed an increase of the autophago-
some number and protein analysis demonstrated an increase
of LC3-II levels. Both parameters can be associated with
either enhanced autophagosome synthesis or reduced
autophagosome turnover. To interpret the changes in levels
of processed LC3-II, it is necessary to inhibit the degradation
of autolysosome content. In the presence of inhibitors (such
as BafA1), accumulation of LC3-II-positive autophagosomes
would be evidence of efficient autophagic flux, whereas failure
of LC3-II to increase would indicate a defect or delay earlier in
the process, prior to degradation at the autolysosome.24,27
From western blot results, we concluded that in our model,
Smn reduction caused increased autophagosome production,
but not alterations in the autophagic flux. LC3-II increase can
be counteracted by Bcl-xL overexpression, which promotes
morphological recovery of Smn-reduced MNs.22 These
results together suggest that an increase of Beclin1-depen-
dent autophagy could be one of the mechanisms responsible
for MNs degeneration in the Smn knockdown model.
Beclin1 is a Bcl-2- and Bcl-xL-interacting protein essential
for autophagosome formation and autophagy initiation.32,33
Its BH3 domain binds to Bcl-2 and Bcl-xL,
34 thus reducing
Beclin1-dependent autophagy.28 The interaction between
Beclin1 and its inhibitors is dynamic and subject to phosphor-
ylation of either partner in the complex,35 and it has been
proposed that Beclin1 phosphorylation and dissociation from
Bcl-xL proteins initiates Beclin1-dependent autophagy.
36 In
our studies, Beclin1 protein level is slightly, but significantly,
increased in Smn-reduced MNs, a change suggesting that
Beclin1 and Beclin1-dependent autophagy may be mediating
autophagosome formation and LC3-II increase in these cells.
In some pathological models of neuronal injury, increased
Beclin1 expression at the lesion site19,37,38 has been
associated with increased autophagy and autophagic cell
death in that region. Thus, Beclin1-dependent autophagy is
involved in neuronal degeneration observed in several injury
models, suggesting an important role of this cell death
mechanism in damaged neurons.
Autophagy is essential for tissue homeostasis. When
autophagosome formation is compromised or when autopha-
gosomes accumulate, cell functions and survival may be
reduced. In the nervous system, autophagy can be the main
route for the degradation of toxic proteins. In some neurode-
generative disorders, especially those caused by aggregates
of mutant forms of specific proteins, there is an accumulation
of autophagosomes that may interfere with intracellular
trafficking or may become a source of cytotoxic products.14,39
On the other hand, mutations that perturb axonal transport
can cause substantial autophagosome accumulation, which
in turn can perturb axonal transport, leading to progressive
neuronal degeneration.12,40 Moreover, autophagosome accu-
mulation can contribute to production of toxic aggregated
proteins.41 In SMA pathogenesis, axonal deficiencies have
been described in several in vitro and in vivo models.8,22,42,43
However, there are no evidences of toxic aggregated protein
accumulation in SMA neurons and non-neuronal cells. The
origin of the axonal degeneration is not clear, although
autophagosome accumulation or transport impairment may
be contributing to this process. For example, autophagy
inhibition by knocking down Beclin1 efficiently delays neurite
degeneration after neurotrophic factor deprivation,20 which
suggests an essential role of autophagy activation in inducing
neurite degeneration after neuronal damage such as trophic
support withdrawal. However, autophagy suppression
induces degeneration of the axon terminals in non-damaged
neurons, which is suggestive of autophagy involvement in
axon homeostasis.44 Therefore, the existence of autophagy
as a pro-death pathway is controversial, and the mechanism
by which autophagy programs neurites to die is still unclear.
Our studies of Smn-reduced MNs reveal an increase of the
autophagosome synthesis but not an alteration of autophago-
some turnover. Therefore, stimulation of autophagosome
production could be detrimental for the integrity of neurites and
neurons. The implication is that drugs that induce autophagy
should not be considered for use in the treatment of SMA.
In summary, our results indicate that Smn reduction causes
changes in Beclin1-dependent autophagy and could be one of
the contributors to neurite degeneration observed in MNs of
SMA experimental models. These observations suggest a
critical role of autophagy in neurite degeneration of damaged
neurons and a potentially valuable clue in understanding the
mechanism of axonal and dendritic degeneration, and a
possible therapeutic target in the treatment of SMA.
Materials and Methods
Spinal cord MN isolation and culture. MN cultures were prepared from
embryonic 12.5-day (E12.5) CD1 mouse spinal cord essentially as described.22,45
Isolated cells were pooled in a tube containing culture medium and plated. All
procedures were in accordance with the Spanish Council on Animal Care and
approved by the University of Lleida Advisory Committee on Animal Services.
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Isolated MNs were plated in four-well tissue culture dishes (Nunc, Thermo Fisher
Scientific, Madrid, Spain) for electron microscopy (15 000 cells/well), immuno-
fluorescence (10 000 cells/well) and western blot (50 000 cells/well) analysis.
Culture medium was Neurobasal (Gibco, Invitrogen, Paisley, UK) supplemented
with B27 (Gibco; Invitrogen), horse serum (2% v/v), L-glutamine (0.5 mM) and 2-
mercaptoethanol (25 mM). Cells were plated with complete medium containing a
cocktail of recombinant NTFs (1 ng/ml brain-derived neurotrophic factor, 10 ng/ml
glial cell line-derived neurotrophic factor, 10 ng/ml ciliary neurotrophic factor, 10 ng/
ml cardiotrophin-1 and 10 ng/ml hepatocyte growth factor; Peprotech, London, UK).
SMA animals. SMA type I mice FVB.Cg-Tg(SMN2)89AhmbSmn1tm1Msd/J were
kindly provided by Dr. Josep E Esquerda (IRBLLEIDA-Universitat de Lleida).
Heterozygous animals were crossed to obtain homozygous Smn / ;SMN2þ /þ
(mtSMA). Littermates mtSMA and Smnþ /þ ;SMN2þ /þ (WT) were used for the
experiments. For MNs purification E13 embryos were removed from the uterus
and a piece was snipped from the head for genotyping. The REDExtract-N-Amp
Tissue PCR Kit (Sigma, St Louis, MO, USA) was used for genomic DNA extraction
and PCR setup, with the following primers: WT forward 50-CTCCGGATATTGG-
GATTG-30, SMA reverse 50-GGTAACGCCAGGGTTTTCC-30 and WT reverse 50-
TTTCTTCTGGCTGTGCCTTT-30. After genotyping, WT and mtSMA animals were
submitted to spinal cord dissection, MN isolation and culture as described before.
Western blot analysis. Western blots were performed as described.45,46
Total cell lysates were resolved in SDS-polyacrylamide gels and transferred onto
polyvinylidene difluoride Immobilon-P transfer membrane filters (Millipore, Billerica,
MA, USA) using an Amersham Biosciences semidry Trans-Blot (Buckinghamshire,
UK). The membranes were blotted with anti-SMN antibody (1 : 5000); anti-Bcl-xL
antibody (1 : 2000; BD Transduction Laboratories, Franklin Lakes, NJ, USA); anti-
LC3 antibody (1 : 1000); anti-Beclin1 antibody (1 : 1000; Cell Signaling Technology,
Boston, MA, USA). To control the specific protein content per lane, membranes
were reprobed with monoclonal anti-a-tubulin antibody (Sigma). Blots
were developed using Super Signal chemiluminiscent substrate (Pierce, Rockford,
IL, USA).
Plasmids and production of lentiviral particles. For RNA inter-
ference experiments, constructs were generated in pSUPER.retro.puro (Oligo-
Engine, Seattle, WA, USA) using specific oligonucleotides (Invitrogen) targeting SMN
sequence as described.22 pLVTHM, pSPAX2 and pMD2G were kindly provided by
Dr. Trono (University of Geneva, Switzerland). Viruses at 4 105–1 106 TU/ml
were used for the experiments. For lentiviral transduction, MNs were plated in four-
well dishes. Medium containing lentivirus (2 TU/cell) was added 3 h later, and then
changed after 20 h. In each experiment, green fluorescent protein (GFP)-positive
cells were counted directly to monitor infection efficiency. Frequency of infection
rose 99%.22,47
For Bcl-xL overexpression, cDNA for human Bcl-xL was subcloned into pWPI as
described previously.48
Electron microscopy. MNs were plated on round glass coverslips and
transduced. Cultures were fixed for 1 h at 41C in 1.6% glutaraldehyde in 0.5 M
phosphate buffer (pH 7.3), washed, fixed again in aqueous 2% osmium tetroxide,
stained in 2% uranyl acetate in 30% methanol and finally embedded in Eppon.
Ultrathin sections were taken from selected areas containing MN cell bodies and
neurites previously identified in toluidine blue-stained 1-mm-thick semithin
sections. Ultrathin sections were stained with lead citrate and uranyl acetate
and observed by electron microscopy (Zeiss EM910, Oberkochen, Germany): one
researcher loaded the section, another examined it and a third counted the
organelles, blinded to which condition was loaded.
Immunofluorescence. MNs were plated on round glass coverslips and
transduced with the lentiviral constructs. After several days cells were fixed with
ice-cold methanol, permeabilized with 0.1% Triton X-100 and incubated for 2 h in
1 ml 5% BSA in PBS. Primary antibody (LC3B antibody, Cell Signaling
Technology) was added at 1 : 100 dilution to the 5% BSA/PBS and incubated
overnight. Cells were washed and the secondary antibody ALEXA555 (Invitrogen)
added at 1 : 400 dilution. Hoechst staining was performed to identify nuclear
localization in MNs soma. Samples were mounted using Mowiol (Calbiochem
(EMD Millipore), Darmstadt, Germany) plus 0.5% DABCO (Sigma) mounting
medium. Microscopy observations were performed in FV10I Olympus confocal
microscope (Tokyo, Japan).
Statistical analysis. All experiments were performed at least three times.
Values were expressed as mean ±S.E.M. Differences between groups were
assessed by one-way ANOVA of lentiviral-transduced cultures at each time point;
if significant, post-hoc multiple comparisons were done using Bonferroni test;
P-values o0.05 were considered significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by grants from GENAME
(Defining targets for Therapeutics in SMA) to RMS; from Instituto de Salud Carlos
III, Fondo de Investigaciones Sanitarias (PI11-01047), Generalitat de Catalunya
(SGR740) and Consolider-Ingenio 2010 (CSD2007-00020) to RMS. AG holds a
post-doctoral contract from Genoma Espan˜a; SA holds a fellowship from Universitat
de Lleida and AP holds a fellowship from Comissionat de Universitats i Recerca,
Departament d’Innovacio´, Universitats i Empresa de la Generalitat de Catalunya
and Fons Social Europeu. We thank Elaine Lilly, Ph.D. (Writer’s First Aid), for
English language revision of the manuscript.
1. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al. Identification
and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:
155–165.
2. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in
autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15: 228–237.
3. Sumner CJ. Therapeutics development for spinal muscular atrophy. NeuroRx 2006; 3:
235–245.
4. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M et al. SMN deficiency causes tissue-
specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell
2008; 133: 585–600.
5. Cifuentes-Diaz C, Nicole S, Velasco ME, Borra-Cebrian C, Panozzo C, Frugier T et al.
Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal
muscular atrophy mouse model. Hum Mol Genet 2002; 11: 1439–1447.
6. Kong L, Wang X, Choe DW, Polley M, Burnett BG, Bosch-Marce M et al. Impaired synaptic
vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice.
J Neurosci 2009; 29: 842–851.
7. Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. Selective
vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the
neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet
2008; 17: 949–962.
8. Rossoll W, Jablonka S, Andreassi C, Kroning AK, Karle K, Monani UR et al. Smn, the
spinal muscular atrophy-determining gene product, modulates axon growth and
localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003; 163:
801–812.
9. Soler-Botija C, Ferrer I, Gich I, Baiget M, Tizzano EF. Neuronal death is enhanced and
begins during foetal development in type I spinal muscular atrophy spinal cord 2002.
Brain 125: 1624–1634.
10. Tsai MS, Chiu YT, Wang SH, Hsieh-Li HM, Lian WC, Li H. Abolishing Bax-dependent
apoptosis shows beneficial effects on spinal muscular atrophy model mice. Mol Ther 2006;
13: 1149–1155.
11. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006; 443:
796–802.
12. Marino G, Madeo F, Kroemer G. Autophagy for tissue homeostasis and neuroprotection.
Curr Opin Cell Biol 2011; 23: 198–206.
13. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular
self-digestion. Nature 2008; 451: 1069–1075.
14. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG et al. Inhibition of mTOR
induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse
models of Huntington disease. Nat Genet 2004; 36: 585–595.
15. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of
mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305:
1292–1295.
16. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH et al. Autophagy induction and
autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s
disease. J Neurosci 2008; 28: 6926–6937.
17. Lee JA, Gao FB. Inhibition of autophagy induction delays neuronal cell loss caused by
dysfunctional ESCRT-III in frontotemporal dementia. J Neurosci 2009; 29: 8506–8511.
18. Chen S, Zhang X, Song L, Le W. Autophagy dysregulation in amyotrophic lateral sclerosis.
Brain Pathol 2012; 22: 110–116.
19. Kanno H, Ozawa H, Sekiguchi A, Itoi E. Spinal cord injury induces upregulation of Beclin 1
and promotes autophagic cell death. Neurobiol Dis 2009; 33: 143–148.
20. Yang Y, Fukui K, Koike T, Zheng X. Induction of autophagy in neurite degeneration of
mouse superior cervical ganglion neurons. Eur J Neurosci 2007; 26: 2979–2988.
SMN reduction deregulates autophagy in motoneurons
A Garcera et al.
7
Cell Death and Disease
21. Yang Y, Xu K, Koike T, Zheng X. Transport of autophagosomes in neurites of PC12 cells
during serum deprivation. Autophagy 2008; 4: 243–245.
22. Garcera A, Mincheva S, Gou-Fabregas M, Caraballo-Miralles V, Llado J, Comella JX et al.
A new model to study spinal muscular atrophy: neurite degeneration and cell death is
counteracted by BCL-X(L) overexpression in motoneurons. Neurobiol Dis 2011; 42:
415–426.
23. Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Biol 2004; 36:
2491–2502.
24. Menzies FM, Moreau K, Puri C, Renna M, Rubinsztein DC. Measurement of autophagic
activity in mammalian cells. Curr Protoc Cell Biol 2012; Chapter 15, Unit15.16.
25. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1
prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes
and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33–42.
26. Fader CM, Colombo MI. Autophagy and multivesicular bodies: two closely related partners.
Cell Death Differ 2009; 16: 70–78.
27. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221:
117–124.
28. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al. Bcl-2 antiapoptotic
proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927–939.
29. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398–6406.
30. Kimura S, Fujita N, Noda T, Yoshimori T. Monitoring autophagy in mammalian cultured
cells through the dynamics of LC3. Methods Enzymol 2009; 452: 1–12.
31. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after
processing. Embo J 2000; 19: 5720–5728.
32. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex
functions at the trans-golgi network. EMBO Rep 2001; 2: 330–335.
33. Erlich S, Mizrachy L, Segev O, Lindenboim L, Zmira O, Adi-Harel S et al.
Differential interactions between Beclin 1 and Bcl-2 family members. Autophagy 2007;
3: 561–568.
34. Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex:
Beclin 1 is a novel BH3-only protein. J Biol Chem 2007; 282: 13123–13132.
35. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and
apoptosis. Cell Death Differ 2011; 18: 571–580.
36. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M et al. DAP-kinase-
mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1
from Bcl-XL and induction of autophagy. EMBO Rep 2009; 10: 285–292.
37. Diskin T, Tal-Or P, Erlich S, Mizrachy L, Alexandrovich A, Shohami E et al. Closed head
injury induces upregulation of Beclin 1 at the cortical site of injury. J Neurotrauma 2005; 22:
750–762.
38. Penas C, Font-Nieves M, Fores J, Petegnief V, Planas A, Navarro X et al. Autophagy, and
BiP level decrease are early key events in retrograde degeneration of motoneurons. Cell
Death Differ 2011; 18: 1617–1627.
39. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci
2010; 13: 805–811.
40. Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from
development to late age. Autophagy 2008; 4: 590–599.
41. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH et al. Macroautophagy–
a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell
Biol 2005; 171: 87–98.
42. McGovern VL, Gavrilina TO, Beattie CE, Burghes AH. Embryonic motor axon development
in the severe SMA mouse. Hum Mol Genet 2008; 17: 2900–2909.
43. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival
motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10:
597–609.
44. Komatsu M, Wang QJ, Holstein GR, Friedrich VL Jr, Iwata J, Kominami E et al.
Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and
the prevention of axonal degeneration. Proc Natl Acad Sci USA 2007; 104:
14489–14494.
45. Gou-Fabregas M, Garcera A, Mincheva S, Perez-Garcia MJ, Comella JX, Soler RM.
Specific vulnerability of mouse spinal cord motoneurons to membrane depolarization.
J Neurochem 2009; 110: 1842–1854.
46. Perez-Garcia MJ, Cena V, de Pablo Y, Llovera M, Comella JX, Soler RM. Glial cell line-
derived neurotrophic factor increases intracellular calcium concentration. Role of calcium/
calmodulin in the activation of the phosphatidylinositol 3-kinase pathway. J Biol Chem
2004; 279: 6132–6142.
47. Mincheva S, Garcera A, Gou-Fabregas M, Encinas M, Dolcet X, Soler RM. The canonical
nuclear factor-{kappa}B pathway regulates cell survival in a developmental model of spinal
cord motoneurons. J Neurosci 2011; 31: 6493–6503.
48. Gozzelino R, Sole C, Llecha N, Segura MF, Moubarak RS, Iglesias-Guimarais V et al.
BCL-XL regulates TNF-alpha-mediated cell death independently of NF-kappaB, FLIP and
IAPs. Cell Res 2008; 18: 1020–1036.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
SMN reduction deregulates autophagy in motoneurons
A Garcera et al.
8
Cell Death and Disease
